Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT03243266 Completed - Healthy Subjects Clinical Trials

DxH520 Pediatric Reference Interval Verification

Start date: June 19, 2017
Phase:
Study type: Observational

Results from this study will be used to verify that the published pediatric reference intervals are met on the DxH 520 Hematology Analyzer for the pediatric age ranges.

NCT ID: NCT03237988 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

Start date: July 20, 2017
Phase: Phase 1
Study type: Interventional

This will be a Phase 1, open-label, randomized, 3-way crossover study to evaluate PK, safety, and tolerability of a new tablet formulation of CPI-444 and to evaluate the effect of food on single oral doses of CPI-444 tablets in healthy male and female subjects. Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration.

NCT ID: NCT03230383 Completed - Healthy Subjects Clinical Trials

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

This will be an investigator- and subject-blinded (sponsor open), randomized, placebo controlled, sequential, ascending, multiple oral dose study, with 5 planned cohorts (optional sixth and seventh cohorts). A total of approximately 50 (if 5 cohorts), 60 (if 6 cohorts), and up to 70 (if 7 cohorts) subjects will be randomized in this study. Subjects in each cohort will be randomized to receive PF-06865571 or matching placebo with approximately 10 subjects dosed in each cohort. For a given subject in any cohort, the total study duration from screening to follow-up phone call will be between approximately 7 to 11 weeks.

NCT ID: NCT03224793 Completed - Healthy Subjects Clinical Trials

Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.

Start date: October 4, 2017
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of single, subcutaneous (SC) doses of BIIB059 in healthy Japanese subjects.

NCT ID: NCT03221374 Completed - Healthy Subjects Clinical Trials

Mind-body Awareness Training and Brain-computer Interface

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

Mind-Body Awareness Training (MBAT), in the forms of various yoga and meditative practices, has become increasingly prevalent due to an increase in awareness of the potential health benefits, and improvements in concentration that this training can provide to practitioners. In the present study, the role of Mind-Body Awareness Training (MBAT) in the initial learning of a sensorimotor (SMR) based Brain-Computer Interface (BCI) is being investigated. The hypothesis is that MBAT will improve performance in SMR based BCI.

NCT ID: NCT03217942 Completed - Healthy Subjects Clinical Trials

Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model

Start date: July 1, 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to investigate and determine the time course and distribution on muscle hyperalgesia and muscle pain in a repeated, low dose NGF model. It is hypothesized that low dosages i.m injections of NGF are able to induce mechanical hyperalgesia and muscle soreness in a same manner (effect of duration) as for dosages previously used in NGF studies. Furthermore, it is also speculated if several injections of low dose NGF into the muscle combined are able to course immediate pain sensation and spreading of muscle hypersensitivity.

NCT ID: NCT03215966 Completed - Healthy Subjects Clinical Trials

A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

Start date: August 7, 2017
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed combination (i.e. whether the amounts of macitentan and tadalfil which reach the blood are comparable).

NCT ID: NCT03173625 Completed - Healthy Subjects Clinical Trials

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Start date: November 29, 2016
Phase: Phase 1
Study type: Interventional

The main objective of the study is to investigate the safety and tolerability of single ascending doses of AC-076 administered as subcutaneous injection

NCT ID: NCT03165097 Completed - Healthy Subjects Clinical Trials

Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects

Start date: July 7, 2017
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety and tolerability of ascending multiple doses of ACT-709478 in healthy male and female subjects

NCT ID: NCT03165071 Completed - Healthy Subjects Clinical Trials

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Start date: June 3, 2017
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to investigate the fate of ACT-132577 in healthy subjects and in people with severe kidney disease